Skip to main content
    F

    Fortress Biotech Inc (FBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.91
    +0.01 (+0.53%)

    Market Cap: $69.37M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    +3.72%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.27
    Range$-0.27 - $-0.27
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.15-80.0%
    60d ago$-0.15-80.0%
    30d ago$-0.15-80.0%
    7d ago$-0.15-80.0%
    Current$-0.27
    Revenue Consensus
    $22M
    Range$22M - $22M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$3.24
    Range$3.24 - $3.24
    1 analysts
    Revenue Consensus
    $23M
    Range$23M - $23M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$3.24---
    Sep 26EST
    		-$-0.27---
    Jun 26
    Reported Aug 13
    		$-0.08N/A+60.00%Beat+84.3%
    Mar 26
    Reported May 14
    		$2.82$-0.22+1381.82%Beat+687.5%
    Dec 25
    Reported Mar 31
    		$-0.21$0.11-290.91%Miss+29.8%
    Sep 25
    Reported Nov 14
    		$0.11N/A+117.74%Beat+114.5%
    Jun 25
    Reported Aug 14
    		$-0.51$-0.31-64.52%Miss+30.1%
    Mar 25
    Reported May 21
    		$-0.48$-0.44-9.09%Miss+53.4%
    Dec 24
    Reported Mar 27
    		$-0.30N/A+60.09%Beat+76.6%
    Sep 24
    Reported Nov 14
    		$-0.76$-0.27-181.48%Miss+19.1%
    Jun 24
    Reported Aug 13
    		$-0.73$-1.22+40.16%Beat+30.5%
    Mar 24
    Reported May 15
    		$-1.03$-1.73+40.46%Beat-14.4%
    Dec 23
    Reported Mar 28
    		$-1.28$-1.97+35.03%Beat-326.7%
    Sep 23
    Reported Nov 14
    		$-0.94$-1.50+37.33%Beat+21.7%
    Jun 23
    Reported Aug 14
    		$-1.05$-0.90-16.67%Miss+30.0%
    Mar 23
    Reported May 15
    		$-0.90$0.45-300.00%Miss+14.3%
    Dec 22
    Reported Mar 30
    		$-0.30$-0.22-36.36%Miss+21.1%
    Sep 22
    Reported Nov 14
    		$-1.20$-1.05-14.29%Miss-114.8%
    Jun 22
    Reported Aug 11
    		$-1.50$-1.12-33.93%Miss+41.2%
    Mar 22
    Reported May 12
    		$-1.05$0.15-800.00%Miss+22.2%
    Dec 21
    Reported Mar 28
    		$-0.38$0.18-311.11%Miss-660.0%
    Sep 21
    Reported Nov 15
    		$8.10$-2.85+384.21%Beat+368.2%
    Jun 21
    Reported Aug 16
    		$-2.55$-1.80-41.67%Miss+10.2%
    Mar 21
    Reported May 16
    		$-1.35$-0.70-92.86%Miss+53.6%
    Dec 20
    Reported Mar 31
    		$-0.05N/A+64.29%Beat+81.5%
    Sep 20
    Reported Nov 9
    		$-3.02$-2.10-43.81%Miss+8.5%
    Jun 20
    Reported Aug 10
    		$-2.84$-2.50-13.60%Miss+21.1%
    Mar 20
    Reported May 11
    		$-2.91$-3.60+19.17%Beat-1070.0%
    Dec 19
    Reported Mar 16
    		$-0.27$-0.31+12.90%Beat+53.4%
    Sep 19
    Reported Nov 12
    		$-3.30$-5.10+35.29%Beat+40.5%
    Jun 19
    Reported Aug 9
    		$-3.60$-6.00+40.00%Beat+52.0%
    Mar 19
    Reported May 10
    		$0.30N/A+103.45%Beat+104.1%
    Dec 18
    Reported Mar 18
    		$-0.58$-0.58+0.00%Beat-163.6%
    Sep 18
    Reported Nov 9
    		$-5.55$-8.55+35.09%Beat+44.8%
    Jun 18
    Reported Aug 9
    		$-7.50$-8.80+14.77%Beat-16.3%
    Mar 18
    Reported May 10
    		$-7.35$-6.00-22.50%Miss-63.3%
    Dec 17
    Reported Mar 16
    		$-0.22N/A+65.08%Beat+50.0%
    Sep 17
    Reported Nov 9
    		$-10.05$-6.37-57.77%Miss-
    Jun 17
    Reported Aug 9
    		$-6.45$-4.42-45.93%Miss-
    Mar 17
    Reported May 10
    		$-4.50$-5.40+16.67%Beat-
    Dec 16
    Reported Mar 16
    		$-0.44$-0.31-41.94%Miss-

    Key Metrics

    Valuation
    P/E Ratio0.72EV/EBITDA-0.61x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin163.30%Operating Margin-53.50%
    ROE116.00%ROIC58.96%
    Financial Health
    Debt/Equity0.24xInterest Coverage15.79x
    Current Ratio3.96xQuick Ratio3.83x
    Trading Statistics
    Beta1.25Avg Volume277.40K
    52-Week High$4.5352-Week Low$1.93

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.03
    SMA 20$2.16
    SMA 50$2.50
    SMA 200$2.90
    EMA 10$2.03
    EMA 20$2.16
    EMA 50$2.43
    EMA 200$2.71

    MACD

    Line: -0.17Signal: -0.16Hist: -0.00

    ADX

    ADX: 42.3+DI: 12.3-DI: 36.0

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$2.15

    Bollinger Bands

    Upper Band$2.50
    Lower Band$1.81
    %B Position3213%(Upper)
    Band Width0.14

    RSI (14-Day)

    Oversold
    26.6

    Momentum Oscillators

    Stoch %K5.7
    Stoch %D12.2
    Williams %R-92.3
    ROC (10d)-7.7%
    Momentum-0.16
    CCI (20d)-119.9
    MFI (14d)31.4

    Volatility Measures

    ATR (14d)$0.09(5.0%)
    StdDev (20d)0.17
    Hist Vol44.1%(High)

    Volume Flow

    VWAP$1.92
    OBV2.6M
    AD Line-6.2M
    CMF (20d)-0.313

    Volume Metrics

    Avg Vol (20d)279.1K
    Vol Ratio0.8x
    VWMA (20d)$2.16

    Pivot Points

    R3$2.00
    R2$1.97
    R1$1.94
    Pivot Point$1.91
    S1$1.87
    S2$1.84
    S3$1.81

    Advanced Oscillators

    TSI-43.73
    Ultimate Osc37.7
    KST-215.51

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$18.72M$16.04M$16.08M$17.63M$16.41M$13.14M$15.16M$14.63M$14.86M$13.03M$19.95M$34.75M
    Cost of Revenue$6.14M$6.22M$5.44M$5.75M$4.94M$4.79M$4.68M$4.47M$5.73M$6.00M$2.25M$6.43M
    Gross Profit$12.57M$9.82M$10.64M$11.88M$11.47M$8.35M$10.48M$10.16M$9.13M$7.03M$17.70M$28.32M
    Operating Expenses$22.58M$17.56M$15.26M$18.69M$47.95M$30.67M$34.37M$32.25M$36.96M$43.59M$37.31M$42.08M
    R&D$805,000$540,000$-371,000$208,000$8.13M$3.94M$9.93M$9.45M$12.67M$24.84M$14.07M$20.35M
    SG&A$20.81M$15.89M$14.56M$17.41M$38.76M$25.66M$26.97M$21.99M$20.82M$17.94M$19.47M$21.73M
    Operating Income$-10,006,000$-7,739,000$-4,620,000$-6,811,000$-36,473,000$-22,317,000$-23,930,000$-22,095,000$-27,788,000$-36,566,000$-19,612,000$-13,758,000
    Interest Income$1.66M$570,000$637,000$736,000$27.75M$490,000$527,000$589,000$734,000$833,000$705,000$547,000
    Interest Expense$1.48M$3.37M$2.04M$2.74M$2.52M$2.81M$2.59M$6.21M$2.12M$2.60M$2.06M$2.53M
    Income Before Tax$922,000$142.29M$-30,734,000$8.85M$-11,654,000$-24,691,000$-65,094,000$-26,625,000$-28,824,000$0$-28,604,000$-10,583,000
    Income Tax Expense$320,000$5.13M$0$26,000$0$0$0$69,000$0$0$0$141,000
    Net Income$602,000$137.16M$-5,397,000$8.83M$-11,654,000$-24,691,000$-26,314,000$-26,694,000$-28,824,000$-39,023,000$-28,984,000$-10,724,000
    EBITDA$2.02M$147.77M$-3,143,000$12.34M$-35,278,000$-20,890,000$-24,945,000$-17,293,000$-25,489,000$-35,454,000$-25,549,000$-6,748,000
    EBIT$735,000$145.09M$-4,639,000$10.86M$-36,885,000$-22,376,000$-24,004,000$-21,005,000$-27,436,000$-37,254,000$-27,249,000$-8,596,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FBIO

    News

    Fortress Biotech stock gains as USD 15.0 million debt is repaid

    Fortress Biotech (FBIO) stock saw gains after the company repaid $15.0 million of debt to Oaktree, settling the remaining principal of a $50.0 million senior secured agreement. The company also reported a 14 percent...

    AD HOC NEWS•10/5/26•Bullish

    Fortress Biotech repaid $15.0M and terminated Oaktree secured credit facility

    Fortress Biotech has repaid the remaining $15.0 million of its Oaktree senior secured credit facility and terminated the agreement. The company also paid approximately $435,000 in accrued interest and a $150,000...

    TradingView•10/1/26•Bullish

    CNB0 Bond Profile: Coupon and Redemption

    This article provides a detailed profile of the Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock...

    TradingView•9/29/26•Neutral

    Fortress Biotech (NASDAQ:FBIO) Posts Earnings Results, Beats Estimates By $0.12 EPS

    Fortress Biotech (NASDAQ:FBIO) announced its quarterly earnings, reporting an adjusted loss of $0.08 per share...

    MarketBeat•8/13/26•Bullish

    Fortress Biotech 2026: Revenue $17.84M, Net income ($2.48M), EPS ($0.08) — 10-Q Summary

    Fortress Biotech (FBIO) reported its financial results for the quarter ended in 2026, showing product revenue of $17.84 million, an 18.9% increase year-over-year. Despite the revenue growth...

    TradingView•8/13/26•Somewhat-Bearish

    FBIO Valuation and Fair Value

    P/E
    0.7x
    Forward P/E
    1.2x
    EV/EBITDA
    -0.6x
    PEG
    -0.1x
    P/B
    0.4x
    See GNG's fair value

    FBIO Profitability: Margins, ROIC and FCF

    Gross margin
    65.6%
    Operating margin
    -53.5%
    Net margin
    163.3%
    ROIC
    59.0%
    ROE
    116.0%
    FCF margin
    183.9%

    FBIO Competitors

    CompanyTicker
    Coeptis Therapeutics IncCOEP
    Heron TherapeutiHRTX
    Oncolytics Biotech IncONCY
    Cingulate IncCING
    MAIA Biotechnology Inc.MAIA
    Microbot Medical IncMBOT
    Outset Medical IncOM
    Spero Therapeutics IncSPRO

    Sector: Healthcare

    FBIO Bull Case vs Bear Case

    Bull case

    • FBIO earns a 59.0% return on invested capital.
    • FBIO converts 183.9% of revenue into free cash flow.
    • FBIO has a 163.3% net profit margin.

    FBIO Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    134.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.27
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About FBIO

    Does FBIO pay dividends?

    Fortress Biotech Inc (FBIO) does not currently pay a regular dividend.

    What is FBIO's P/E ratio?

    Fortress Biotech Inc has a price-to-earnings (P/E) ratio of 0.72.

    What is FBIO's market cap?

    Fortress Biotech Inc (FBIO) has a market capitalization of $69.37M with a current stock price of $1.91.

    Related stocks

    Sector: Healthcare

    All stocks starting with F

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In